Lipoprotein(a): the enemy that we still don’t know how to defeat-Reference-Cited by-同舟云学术

Lipoprotein(a): the enemy that we still don’t know how to defeat

Published:2023-07 Issue:4 Volume:3 Page:
ISSN:2752-4191
Container-title:European Heart Journal Open
language:en
Short-container-title:

Author:

Banach Maciej¹²³⁴^ORCID

Affiliation:

1. Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL) , Rzgowska 281/289, 93-338 Lodz , Poland

2. Department of Cardiology and Adult Congenital Heart Diseases, Polish Mother’s Memorial Hospital Research Institute (PMMHRI) , Rzgowska 281/289, 93-338 Lodz , Poland

3. Cardiovascular Research Centre, University of Zielona Gora , Zyty 28, 65-046 Zielona Gora , Poland

4. Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine , 600 N. Wolfe St, Carnegie 591, Baltimore, MD 21287 , USA

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/ehjopen/article-pdf/3/4/oead080/51273050/oead080.pdf

Reference15 articles.

1. Targeted treatment against lipoprotein (a): the coming breakthrough in lipid lowering therapy;Sosnowska;Pharmaceuticals (Basel),2022

2. Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: a survey among the Lipid Clinics Network;Catapano;Atherosclerosis,2023

3. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement;Kronenberg;Eur Heart J,2022

4. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021;Banach;Arch Med Sci,2021

5. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society;Kronenberg;Atherosclerosis,2023

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Causal associations between insulin and Lp(a) levels in Caucasian population: a Mendelian randomization study;Cardiovascular Diabetology;2024-08-29

2. The prevalence, patients' characteristics, and hyper-Lp(a)-emia risk factors in the Polish population. The first results from the PMMHRI-Lp(a) Registry;Progress in Cardiovascular Diseases;2024-08

3. Influence of Dulaglutide on Serum Biomarkers of Atherosclerotic Plaque Instability: An Interventional Analysis of Cytokine Profiles in Diabetic Subjects—A Pilot Study;Medicina;2024-05-30

4. Association between lipoprotein(a) and premature atherosclerotic cardiovascular disease: a systematic review and meta-analysis;European Heart Journal Open;2024-04-26

5. Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels;Archives of Medical Science;2024-01-31